Biricodar
From Wikipedia, the free encyclopedia
Biricodar
 |
| Systematic (IUPAC) name |
| 1,7-di(pyridin-3-yl)heptan-4-yl (2S)-1-[oxo(3,4,5-trimethoxyphenyl)acetyl]piperidine-2-carboxylate |
| Clinical data |
| Pregnancy cat. |
? |
| Legal status |
? |
| Identifiers |
| CAS number |
174254-13-8 |
| ATC code |
None |
| PubChem |
CID 3037617 |
| ChemSpider |
2301309 Y |
| UNII |
9WQP0L619L Y |
| ChEMBL |
CHEMBL350775 Y |
| Chemical data |
| Formula |
C34H41N3O7 |
| Mol. mass |
603.705 g/mol |
| SMILES |
eMolecules & PubChem |
-
InChI=1S/C34H41N3O7/c1-41-29-20-26(21-30(42-2)32(29)43-3)31(38)33(39)37-19-5-4-16-28(37)34(40)44-27(14-6-10-24-12-8-17-35-22-24)15-7-11-25-13-9-18-36-23-25/h8-9,12-13,17-18,20-23,27-28H,4-7,10-11,14-16,19H2,1-3H3/t28-/m0/s1 Y
Key:CGVWPQOFHSAKRR-NDEPHWFRSA-N Y
|
Y (what is this?) (verify)
|
Biricodar (INN, codename VX-170, marketed as the dicitrate salt under the trade name Incel) is a pharmaceutical drug released by Vertex Pharmaceuticals in 1999 to help treat ovarian cancer patients.
[edit] External links